The Cigna Group a Top Socially Responsible Dividend Stock With 2.0% Yield (CI)

The Cigna Group (CI) is a notable component of the iShares USA ESG Select ETF (SUSA), representing 0.28% of its underlying holdings with $13.97 million in CI shares. Cigna maintains an annualized dividend of $5.6/share, paid quarterly, with its most recent ex-dividend date on December 4, 2024. A DividendRank report emphasizes the critical importance of Cigna's long-term dividend history for assessing the likely continuation and sustainability of its future payouts.

Analysis

The Cigna Group (CI) is highlighted for its dual appeal to income and ESG-focused investors, underscored by its inclusion in the iShares USA ESG Select ETF (SUSA). Within this fund, Cigna constitutes a 0.28% position, with the ETF holding approximately $13.98 million worth of its shares. The company maintains a significant capital return program, distributing an annualized dividend of $5.60 per share in quarterly payments. The article explicitly points to the guidance of a DividendRank report, which stresses that the sustainability of this dividend should be assessed by analyzing the company's long-term payment history. This positions the dividend not just as a current yield metric, but as a fundamental factor requiring historical due diligence. Operating in the Diagnostics sector, Cigna is contextualized alongside peers such as CVS Health Corporation, providing a reference point for industry comparison.

Key Decisions for Investors

• Income-focused investors should scrutinize The Cigna Group's long-term dividend payment history to assess the sustainability and potential for future growth of its current $5.60/share annual payout.
• For portfolios with ESG mandates, Cigna's inclusion in the iShares USA ESG Select ETF (SUSA) serves as a positive screen, though its relatively small 0.28% weighting in the fund should be considered when evaluating its overall ESG significance.
• Investors should benchmark Cigna's dividend characteristics and fundamental profile against direct competitors like CVS Health to ascertain its relative value and positioning within the healthcare sector.